Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

Study summary

The purpose of this study is to examine adherence to cardio-oncology consultation.

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedCardiac Aggressive Risk MitigAtion Plan

The study team can explain what participation involves.

Who it may be forCancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 6, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Cedars-Sinai Medical Center

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Not applicable
Sponsor: Cedars-Sinai Medical Center
Interventions being studied: Other: Cardiac Aggressive Risk MitigAtion Plan

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Any stage (I-IV) malignancy being treated with high dose (≥30 Gy) radiotherapy where the heart is in the treatment field.
Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2.
Planning to receive standard of care radiotherapy treatments.
Access to a smart device that has the capability to sync to the devices.
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Ability to read, write and understand English.

Reasons someone may not be able to joinExclusion criteria

Known allergy to surgical steel or elastomer/rubber.
Heart attack within 6 months prior to study enrollment.
Severe and/or active scleroderma or systemic lupus erythematosus.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Cancer Clinical Trials OfficeLos Angeles, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 6, 2025. Always confirm current availability with the study team.

View original record ↗